Editas Medicine Announces Second Quarter 2019 Results and Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Editas Medicine (EDIT) Reports Q2 Loss of $0.69
August 6, 2019 5:08 PM EDTEditas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.69), versus ($0.82) reported last year. Revenue for the quarter came in at $2.33 million versus the consensus estimate of $7.37 million.
"I am pleased and honored to be appointed CEO at this exciting time for the company," said... More
